We analyzed somatic mutations in AKT1, AKT2, and AKT3 in a cohort of 41,075 human cancers including both retrospective sequencing of largely primary and treatment-naïve tumors from The Cancer Genome Atlas cohort and various published studies combined as described previously11, and prospective sequencing data from the tumor and matched normal specimens of 21,936 patients profiled as part of an institution-wide tumor profiling initiative12 (see “Methods”). This evidence concerns the gene AKT2 and neoplasm.